Metastatic Eccrine Porocarcinoma: A 5.6‐Year Follow‐up Study of a Patient Treated With a Combined Therapeutic Protocol

Background. Metastatic eccrine porocarcinoma (EP) is an uncommon, malignant, and potentially lethal neoplasm that arises from the eccrine sweat glands. Objective. To present the 5.6‐year follow‐up study of a male patient with metastatic EP, highlighting the widespread cutaneous involvement and the r...

Full description

Saved in:
Bibliographic Details
Published in:Dermatologic surgery 2003-12, Vol.29 (12), p.1227-1232
Main Authors: González‐López, Marcos A., Vázquez‐López, Francisco, Soler, Tomás, Gómez‐Diéz, Santiago, Garcia, Yolanda Hidalgo, Manjón, Jose A., López‐Escobar, María, Pérez‐Oliva, Narciso
Format: Article
Language:English
Subjects:
Acrospiroma - pathology
Acrospiroma - therapy
Aged
Biological and medical sciences
Combined Modality Therapy
Dermatology
Follow-Up Studies
Humans
Male
Medical sciences
Neoplasm Metastasis
Skin plastic surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Sweat Gland Neoplasms - pathology
Sweat Gland Neoplasms - therapy
Time Factors
Tumors of the skin and soft tissue. Premalignant lesions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. Metastatic eccrine porocarcinoma (EP) is an uncommon, malignant, and potentially lethal neoplasm that arises from the eccrine sweat glands. Objective. To present the 5.6‐year follow‐up study of a male patient with metastatic EP, highlighting the widespread cutaneous involvement and the response to the treatment carried out. Methods. We describe the evolution of the tumor and the combined therapy carried out and review the treatments employed in previously reported cases, comparing them with ours. Results. The patient developed multiple cutaneous and regional lymph node metastases 15 months after surgical excision of the primary tumor. He was treated with prophylactic lymphadenectomy, radiotherapy, and oral isotretinoin, subsequently substituted by tegafur. We have not found evidence of distant metastases after a 5.6‐year follow‐up. Conclusions. The optimum treatment for metastatic EP is not standardized, and the results obtained to date were generally poor. In this context, we consider it of interest to highlight the response of our patient to the therapeutic regime employed, which may be advantageous in future cases of this rare tumor.
ISSN:1076-0512
1524-4725
DOI:10.1111/j.1524-4725.2003.29393.x